🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesGLP-1 and peripheral arterial disease — my results so far Page 2

GLP-1 and peripheral arterial disease — my results so far

COA_Karl Thu, Mar 5, 2026 at 9:11 AM 8 replies 746 viewsPage 2 of 2
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Mar 5, 2026 at 12:19 PM#6
Dr.GutHealth said:
6 month update on cardiovascular risk: down 46 lbs, off blood pressure meds, A1C normalized.

I read this differently from Dr.GutHealth, on substance rather than tone. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

20 23mike_nyc, VendorMark, COA_Karl and 17 others
Reply Quote Save Share Report
DoseLogDan
Member
201
567
Feb 2025
Montana
Mar 5, 2026 at 1:32 PM#7
COA_Karl said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

21 24Dr.AddMedPHL, newstart_MO, mia_MS2 and 18 others
Reply Quote Save Share Report
hyun_seoul
Member
345
1,456
Jul 2024
Seoul, KR
Mar 5, 2026 at 2:45 PM#8
Dr.GastroMayo said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off amlodipine entirely! My cardiologist is thrilled.

If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.

22 0MASHdoc_SA, GenomicsKate, Dr.ObesityMed and 19 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Mar 5, 2026 at 3:58 PM#9

One thing that is still open after tommy_boulder’s answer:

What did you change at the same time, and can you separate the two now?

23 1NurseKim_ATL, paul_denver, TinaHashiRN and 20 others
Reply Quote Save Share Report
COA_Karl
Senior Member
2,123
8,901
Jan 2024
Pennsylvania
Mar 5, 2026 at 9:47 PM#10
hyun_seoul said:
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off amlodipine entirely!

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

33 6LindaRN_retired, tommy_boulder, hyun_seoul and 30 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register